Su-11248 Sugen.
SUGEN is developing SU-11248, an orally active inhibitor of platelet-derived growth factor tyrosine kinase (TK) and other TK signaling pathways, as a potential anticancer agent. By October 2003, phase III trials for gastrointestinal stromal tumors and renal cell carcinoma were underway.
Sakamoto
Kathleen M
KM
Division of Hematology-Oncology, Mattel Children's Hospital, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095-1752, USA. kms@ucla.edu
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D011758:Pyrroles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000077210:Sunitinib
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib